European Commission grants Orphan Drug Designation to Cellectis' UCART22 for Acute Lymphoblastic Leukemia.

Cellectis, a clinical-stage biotech company, received Orphan Drug Designation from the European Commission for its allogeneic CAR-T product candidate, UCART22, for treating Acute Lymphoblastic Leukemia (ALL). UCART22 targets CD22 and is being evaluated in the Phase 1/2 BALLI-01 study. The company plans to report updates on the study by the end of the year.